Graham Capital Management, L.P. Macrogenics Inc Transaction History

Graham Capital Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $309,347 - $679,804	31,663 New	31,663 $466,000
Q3 2023 Nov 22, 2023	SELL	$4.48 - $6.19 $13,865 - $19,158	-3,095 Reduced 14.44%	18,332 $85,000
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $98,992 - $161,559	21,427 New	21,427 $114,000
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $577,482 - $1.21 Million	-172,899 Reduced 84.2%	32,451 $217,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $478,418 - $829,682	-158,943 Reduced 43.63%	205,350 $710,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $672,700 - $2.99 Million	298,978 Added 457.75%	364,293 $1.07 Million
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $442,913 - $921,827	54,546 Added 506.51%	65,315 $575,000
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $171,334 - $235,625	10,769 New	10,769 $172,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.